Evidence map›Paper›PMID 40969273›Full record

ArticleFrontiers in oncology2025

Prognosis of second primary oral squamous cell carcinoma after hematologic malignancy: a retrospective cohort analysis.

Huajiao Yu, Bo Li, Yu Huang, Xue Zhang, Hanchen Zhou, Zhien Feng, Zhengxue Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huajiao Yu *Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Bo Li *Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Yu HuangDepartment of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Xue ZhangDepartment of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Hanchen ZhouDepartment of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Zhien FengDepartment of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
Zhengxue HanDepartment of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Prognosis and optimal management strategies of second primary oral squamous cell carcinoma (OSCC) following a history of hematologic malignancies (HM) remain uncertain. We investigated whether HM history affects OSCC outcomes or necessitates treatment modifications. Patients and methods: This retrospective cohort study included 2486 OSCC patients: 14 with OSCC as a second primary malignancy post-HM (SPM group) and 2472 with primary OSCC (non-SPM group). Using propensity score matching (PSM), we created two cohorts: 1:17 (13 SPM vs 232 non-SPM) and 1:3 (13 SPM vs 38 non-SPM). Outcomes were disease-free survival (DFS), overall survival (OS), and disease-specific survival (DSS). Survival differences were analyzed using log-rank tests. Multivariate Cox regression identified prognostic predictors. Results: No significant survival differences existed between SPM and non-SPM groups in either cohort (1:17: DFS 53.8% vs 68.9%, p=0.102; OS 69.2% vs 81.3%, p=0.170; DSS 69.2% vs 82.2%, p=0.147. 1:3: DFS 53.8% vs 63.2%, p=0.302; OS 69.2% vs 76.3%, p=0.532; DSS 69.2% vs 78.9%, p=0.430). Cox regression identified independent predictors: DFS: Age (p=0.001), T stage (p<0.001), N stage (p<0.001); OS and DSS: Age (p<0.001), T stage (p<0.001), N stage (p<0.001), pathological grade (p<0.001), prior HM was not an independent predictor. Conclusions: A history of HM does not independently predict the prognosis of second primary OSCC nor necessitate modifications to standard OSCC treatment.

Indexed as

hematologic malignancyoral squamous cell carcinomaprognosissecond primary malignancysurgical treatment

Identifiers

PMID40969273
PMCPMC12442044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.